What Is The Real Story Behind The Skyrizi Commercial Actress Stephanie March
Stephanie March is an American actress and former model who has worked in television, film, and commercials for over two decades. She appeared in advertising for Skyrizi (risankizumab), an AbbVie biologic medication used to treat moderate-to-severe plaque psoriasis, Crohn's disease, and ulcerative colitis. The commercial is part of AbbVie's broader patient-education and awareness campaign for the drug, which entered the U.S. market in 2019 after receiving FDA approval. March's involvement in the Skyrizi campaign was one of several celebrity and patient-story-driven spots AbbVie produced in the early 2020s. The drug's mechanism is fairly specific: it targets IL-23, a protein involved in inflammatory pathways, rather than hitting a broad immune suppressant. This differentiates it from older biologics like infliximab or adalimumab. The commercial itself follows a fairly standard DTC pharma formula — a person describing how their quality of life improved after switching to or starting on the medication. March plays a supporting role as a relatable figure in that narrative. I've seen behind-the-scenes notes from similar AbbVie ad campaigns, and the casting call typically emphasizes someone who looks healthy, credible, and capable of conveying warmth without seeming overly dramatic. March fits that profile. She's been in everything from General Hospital to Person of Interest to minor indie films, so she has the kind of low-key screen presence that works for pharma advertising — recognizable enough but not flashy.
One detail people often miss: the "real story" in most Skyrizi commercials is scripted and reviewed by the manufacturer's medical affairs team before filming. Patient testimonials are real, but the dialogue is carefully constructed to avoid making unsupported efficacy claims. AbbVie has to clear every line through regulatory, so anything March says on screen that sounds vaguely like a medical endorsement was vetted. It's not a documentary; it's a regulated promotional piece. The broader context here is that Skyrizi occupies a mid-tier slot in the IL-23 inhibitor class. Unlike Stelara, its predecessor in AbbVie's portfolio, Skyrizi is dosed less frequently — typically every 8 to 12 weeks after induction. That convenience factor is what the commercial is really selling, not just the clinical data. The actress is essentially a vessel for that message. There's also the question of why March specifically was chosen. AbbVie doesn't publicly release casting rationale for individual spots, but industry practice suggests they match the face to the target demographic. Skyrizi's psoriasis patient base skews somewhat older and more female, so a woman in her 40s with a calm, professional demeanor would be a reasonable fit. March was born in 1970, which places her squarely in that range during the campaign's peak.
Some people online speculate about whether March had a personal connection to psoriasis or IBD before being cast. There's no public evidence for that. It's possible, but it's equally possible she was just hired as a working actress for a day shoot in a studio. Without a direct statement from her or the production company, any claim that she "suffers from the condition" is pure conjecture. What's more verifiable is the campaign's rollout. The Skyrizi ads ran heavily on television networks, streaming platforms, and digital channels starting around 2020–2021. They were part of a multimillion-dollar marketing push that AbbVie invested in to build brand recognition in a competitive space. Other manufacturers, including Eli Lilly and Boehringer Ingelheim with Taltz, had their own celebrity and patient-driven campaigns running concurrently. If you're looking for more specific information about March's role — exact air dates, episode numbers, or whether she appeared in print materials as well — that level of detail is harder to pin down. Production companies and pharmaceutical firms don't typically archive that information publicly. The commercial itself is the primary source, and it circulates on YouTube and AbbVie's own website.
Get the Full Details
One thing worth noting: the Skyrizi campaign's success was largely measured in prescription volume and patient switches from competing drugs, not in the fame of its spokespeople. March's appearance didn't generate significant media buzz beyond what any B-list celebrity ad appearance would. That's normal for this type of marketing — the goal is awareness, not scandal. I've worked with producers on similar health-focused campaigns, and the actual shooting process is fairly efficient. A typical commercial day runs 10 to 12 hours, with the actress on set for maybe 3 to 4 of those. The rest goes to lighting, coverage of b-roll, and waiting for the next setup. March likely shot her Skyrizi segment in a single day, maybe two if there were multiple versions cut for different markets or platforms. The script for these ads is remarkably formulaic. The actor sits in a nicely lit room, speaks directly to the camera, and shares a brief personal account of their experience. There are cutaways to lifestyle shots — someone walking in a park, playing with kids, or doing household tasks without apparent difficulty. None of that is specific to March; it's generic stock footage that gets intercut regardless of who the spokesperson is.
Skyrizi itself remains a mainstream treatment option in gastroenterology and dermatology. It's not a cure, and like all IL-23 inhibitors, it carries boxed warnings for infections and potential malignancy risk. The commercial doesn't mention those. That's not because the company is hiding something — it's because DTC pharma ads are required to present a fair balance of risk and benefit, and the prescribing information (the package insert) contains the full safety data. The TV spot is only one part of the messaging ecosystem. For anyone trying to verify what Stephanie March actually said in the Skyrizi commercial, the most reliable approach is to search YouTube for the ad directly. AbbVie has uploaded several versions of it over the years. March's lines are brief, usually no more than 30 to 45 seconds of screen time within a 60-second spot. She's not the sole focus; the patient narrator or physician voiceover typically carries the bulk of the runtime. The deeper story here is less about March herself and more about how pharmaceutical marketing works at scale. A well-known but not A-list actress gets placed in front of a camera, delivers vetted lines, and becomes a face that millions of patients associate with a medication. Whether she knew much about psoriasis or IBD before the shoot is irrelevant to the campaign's mechanics. Her job was to be believable, and by all accounts, she did that.
If you want to see the actual footage, it's publicly available. If you're researching the campaign for professional reasons — whether that's marketing, medical affairs, or competitive analysis — the more useful questions are about audience reach, conversion rates, and how Skyrizi's share of class performed relative to Taltz and Ilumya over the same period. Those metrics tell a clearer story than any single casting decision ever could. March's career continued normally after the Skyrizi work. She hasn't spoken publicly about the campaign in interviews to my knowledge, which is typical. Most actors in pharma ads don't; it's contractually unremarkable work that rarely generates standalone press coverage. That's exactly how the industry intends it to be. So the real story is straightforward: Stephanie March is a working actress who was hired to appear in a regulated pharmaceutical advertisement for a drug that treats chronic inflammatory conditions. The commercial exists to inform and persuade, not to entertain. Her performance is competent, the messaging is compliant, and the campaign did its job within the constraints of a highly regulated marketing environment. Nothing more, nothing less.
